Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. 2018

Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. spolyzos@auth.gr.

OBJECTIVE The evaluation of (a) noggin levels in patients with simple steatosis (SS) vs. nonalcoholic steatohepatitis (NASH) vs. controls, and (b) the effect of combined spironolactone plus vitamin E vs. vitamin E monotherapy on noggin levels in biopsy-proven patients with nonalcoholic fatty liver disease (NAFLD). METHODS In the case-control study, 15 patients with SS, 16 with NASH, and 24 controls were included. In the randomized controlled trial, NAFLD patients were assigned to vitamin E (400 IU/d) or spironolactone (25 mg/d) plus vitamin E for 52 weeks. RESULTS Noggin levels were lower in SS (5.8 ± 1.5 pmol/l) and NASH (8.7 ± 2.4 pmol/l) patients than in controls (13.7 ± 2.7 pmol/l; p for trend = 0.040), but were similar in SS and NASH patients. After adjustment for potential cofounders, log(noggin) remained different between groups. Log(noggin) levels similarly increased post-treatment in both groups: log(noggin) was not different between groups (p = 0.20), but increased within groups over time (p < 0.001), without a significant group × time interaction (p = 0.62). Log(noggin) significantly increased at month 2 post-treatment (p = 0.008 vs. baseline) and remained stable thereafter. CONCLUSIONS Lower noggin levels were observed in NAFLD patients than in controls. Noggin levels increased similarly by either combined low-dose spironolactone plus vitamin E or vitamin E monotherapy. BACKGROUND NCT01147523.

UI MeSH Term Description Entries
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000451 Mineralocorticoid Receptor Antagonists Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE. Aldosterone Antagonist,Aldosterone Antagonists,Aldosterone Receptor Antagonist,Mineralocorticoid Antagonist,Mineralocorticoid Receptor Antagonist,Aldosterone Receptor Antagonists,Mineralocorticoid Antagonists,Antagonist, Aldosterone,Antagonist, Aldosterone Receptor,Antagonist, Mineralocorticoid,Antagonist, Mineralocorticoid Receptor,Antagonists, Aldosterone,Antagonists, Aldosterone Receptor,Antagonists, Mineralocorticoid,Antagonists, Mineralocorticoid Receptor,Receptor Antagonist, Aldosterone,Receptor Antagonist, Mineralocorticoid,Receptor Antagonists, Aldosterone,Receptor Antagonists, Mineralocorticoid
D013148 Spironolactone A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827) Spirolactone,Aldactone,Aldactone A,Aquareduct,Duraspiron,Espironolactona Alter,Espironolactona Mundogen,Flumach,Frumikal,Jenaspiron,Novo-Spiroton,Practon,SC-9420,Spiractin,Spiro L.U.T.,Spiro Von Ct,Spirobeta,Spirogamma,Spirolang,Spirono-Isis,Spironone,Spirospare,Veroshpiron,Verospiron,Verospirone,Ct, Spiro Von,Novo Spiroton,NovoSpiroton,SC 9420,SC9420,Spirono Isis,Von Ct, Spiro
D014810 Vitamin E A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D065626 Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION. Fatty Liver, Nonalcoholic,NAFLD,Nonalcoholic Fatty Liver Disease,Nonalcoholic Steatohepatitis,Fatty Livers, Nonalcoholic,Liver, Nonalcoholic Fatty,Livers, Nonalcoholic Fatty,Non alcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver,Nonalcoholic Fatty Livers,Nonalcoholic Steatohepatitides,Steatohepatitides, Nonalcoholic,Steatohepatitis, Nonalcoholic

Related Publications

Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
October 2011, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
November 2012, Current opinion in clinical nutrition and metabolic care,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
April 2019, IUBMB life,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
November 2015, World journal of hepatology,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
January 2018, Antioxidants (Basel, Switzerland),
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
January 2011, The American journal of gastroenterology,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
January 2006, Acta gastro-enterologica Belgica,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
August 2013, Metabolic syndrome and related disorders,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
June 2006, The American journal of gastroenterology,
Stergios A Polyzos, and Jannis Kountouras, and Athanasios D Anastasilakis, and Polyzois Makras, and Gerhard Hawa, and Linda Sonnleitner, and Albert Missbichler, and Michael Doulberis, and Panagiotis Katsinelos, and Evangelos Terpos
September 2007, Digestive diseases and sciences,
Copied contents to your clipboard!